Antitumor activity of the selective epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) Iressa® (ZD1839) in an EGFR‐expressing multidrug‐resistant cell line <i>in vitro</i> and <i>in vivo</i>

Ichiro Naruse, Kazuto Nishio, Yoko Ao et al.|International Journal of Cancer|2001

Cited by 89